An Australian cannabis company and a Colombia-based producer have elected to scrap their acquisition deal after an independent business review called the agreement into question.

PharmaCielo (TSXV:PCLO) confirmed on Tuesday (November 5) that the deal has been cancelled because the board of directors for Creso Pharma (ASX:CPH) cannot support the original agreement,

Creso Pharma’s decision comes after a BDO Corporate Finance review indicated the transaction was “neither fair nor reasonable and is not in the best interests of shareholders of Creso Pharma.”

David Attard, CEO of PharmaCielo, said the company is disappointed about the way things ended between the two firms, but still managed to find a positive message.

“(W)e have appreciated the interactions between our teams over the past several months and wish them much success in their future endeavours,” he said.

The original agreement did not include a break fee for any party, PharmaCielo indicated. The only remaining item is an AU$3.8 million secured bridge loan paid to Creso Pharma carrying a 15 percent interest rate per year. This payment, according to the Colombian firm, matures at the end of November.

The purchase deal first started falling through, officially, last Friday (November 1), when PharmaCielo confirmed it needed to make sure the BDO report did not affect the thinking of Creso Pharma.

Both companies had their shares halted after the first signs of a slowdown in the deal. As of the time of this writing, both companies remained halted from trading.

Back in October, Creso Pharma said that its board of directors unanimously recommended the approval of the deal by shareholders of the company.

share price chart creso pharma

PharmaCielo previously indicated it was unwilling to increase its offer.

The original agreement laid out a plan for PharmaCielo to acquire all of the issued and outstanding shares and listed options of Creso Pharma by way of a deal estimated at approximately AU$122 million.

In terms of the perks of the transaction, Miri Halperin Wernli, co-founder and CEO of Creso Pharma, said earlier this year, “This arrangement with PharmaCielo is an incredible opportunity for Creso Pharma shareholders to benefit from being part of a best in class and well-capitalized global medicinal cannabis company.”

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less

It’s been just over a year since recreational cannabis was legalised in the Australian Capital Territory (ACT), home to the nation’s capital city of Canberra.

Announced on September 25, 2019, and brought into effect on January 31, 2020, the rules make it legal to possess and personally use small amounts of cannabis.

Keep reading... Show less

Pac Roots Cannabis Corp. (CSE: PACR) (“PacRoots” or the “Company”), announces the closing of its previously announced non-brokered private placement (see press release dated January 25, 2021).

Aggregate gross proceeds of $1,340,685.90 were raised through the issuance of 7,448,255 units (each a “Unit”). Each Unit consists of one common shares and one share purchase warrant. Each warrant is exercisable at a price of $0.30 per share until February 23, 2024.

Keep reading... Show less

 Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States will release its fourth quarter 2020 financial results on Tuesday, March 23, 2021 before markets open. Following the earnings release, management will host a conference call at 8:30 AM Eastern Time to review the financial results.

All interested parties can join the conference call by dialing 1-888-231-8191 or 1-647-427-7450, conference ID: 7066881. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until March 30, 2021 . To access the archived conference call, please dial 1-855-859-2056 and enter the encore code 7066881.

Keep reading... Show less